Medicine and Health Sciences Commons^™

Acquired Aplastic Anemia: Treatment In A Developing Country., Shaheena Hanif, Farah Naz, Emaduddin Siddiqui, Jamal Raza

Department of Emergency Medicine

Objective:

The aim of this study was to evaluate the clinical presentation of aplastic anemia as well as to assess the efficacy of Cyclosporin -A in patients with aplastic anemia.

Methodology:

This is a hospital based interventional study. During the three year study period, 44 children were enrolled. Mean age was 9.3 years and there was a male predominance.

Results:

Most common clinical presentation was anemia and bleeding. Four children died before therapy was started. Cyclosporin-A was started in 40 patients. Eleven patients died before completion of therapy and three patients were lost to follow-up. Out of 26 patients who …

Cyclosporin Induced Fatal Rhabdomyolysis In A Young Patient With Acquired Aplastic Anemia: A Case Report, M. Usman, S. N. Adil, G. N. Kakepoto, Mohammad Khurshid

Department of Pathology and Laboratory Medicine

Cyclosporin is used as an immunosuppressive agent in the management of a variety of autoimmune disorders1 and in patients of organ transplant to suppress host immunity and prevent rejection.2 It is now well established that acquired aplastic anemia is secondary to immune mediated destruction of stem cells in the bone marrow3 and hence Cyclosporin is used as a first line immunosuppressive drug alone or in combination with anti lymphocyte globulin in the management of aplastic anemia.1 Rhabdomyolysis is a rare side effect of Cyclosporin.4 Here we describe a case of fatal rhabdomyolysis in a young patient who received cyclosporin for …